Imatinib therapy for chronic myeloid leukemia: where do we go now? - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

The International Randomized Study of Interferon and STI571 (IRIS) study prospectively
compared imatinib with interferon-alpha/low-dose cytarabine (IFN/LDAC) in 1,106 newly …

528 Editorials| JNCI Vol. 103, Issue 7| April 6, 2011 the many pieces of efficacy data that
have emerged in the time since the very first phase I IM trial was published (3). The …

Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid
leukemia patients for the past 10 years. Recently, other, possibly better, tyrosine kinase …

Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the
reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a …

We report on long-term outcomes of 267 patients (pts) with chronic myeloid leukemia (CML)
treated with imatinib administered as initial therapy. The median follow-up time was 11.4 …

7045 Background: Imatinib mesylate induces response in most patients with chronic
myelogenous leukemia (CML). Although recent evidence shows benefit from a starting dose …

In this article, the authors briefly recap the key clinical trials that involve imatinib mesylate
(Gleevec, Glivec, STI571). Because the reader may be familiar with many of these …